Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2009

Open Access 01-12-2009 | Original investigation

Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model – the Zucker diabetic rat

Authors: Fabien Forcheron, Alexandra Basset, Pauline Abdallah, Peggy Del Carmine, Nicolas Gadot, Michel Beylot

Published in: Cardiovascular Diabetology | Issue 1/2009

Login to get access

Abstract

Background

Diabetic cardiomyopathy (DCM) contributes to cardiac failure in diabetic patients. It is characterized by excessive lipids accumulation, with increased triacylglycerol (TAG) stores, and fibrosis in left ventricle (LV). The mechanisms responsible are incompletely known and no specific treatment is presently defined. We evaluated the possible usefulness of two molecules promoting lipid oxidation, fenofibrate and metformin, in an experimental model of DCM, the Zucker diabetic rat (ZDF).

Methods

ZDF and controls (C) rats were studied at 7, 14 and 21 weeks. After an initial study at 7 weeks, ZDF rats received no treatment, metformin or fenofibrate until final studies (at 14 or 21 weeks). C rats received no treatment. Each study comprised measurements of metabolic parameters (plasma glucose, TAG, insulin levels) and sampling of heart for histology and measurements of TAG content and relevant mRNA concentration.

Results

ZDF rats were insulin-resistant at 7 weeks, type 2 diabetic at 14 weeks and diabetic with insulin deficiency at 21 weeks. Their plasma TAG levels were increased. ZDF rats had at 7 weeks an increased LV TAG content with some fibrosis. LV TAG content increased in untreated ZDF rats at 14 and 21 weeks and was always higher than in C. Fibrosis increased also moderately in untreated ZDF rats. Metformin and fenofibrate decreased plasma TAG concentrations. LV TAG content was decreased by metformin (14 and 21 weeks) and by fenofibrate (14 weeks). Fibrosis was reduced by fenofibrate only and was increased by metformin. Among the mRNA measured, fenofibrate increased Acyl-CoA Oxidase mRNA level, metformin decreased Acyl-CoA Synthase and increased AdipoR1 and pro-inflammatory mRNA levels.

Conclusion

Fenofibrate had favourable actions on DCM. Metformin had beneficial effect on TAG content but not on fibrosis. PPARα agonists could be useful for the prevention and treatment of DCM.
Appendix
Available only for authorised users
Literature
1.
Diamant M, Lamb H, Groneveld Y, Endert E, Smit J, Bax J, Romijn J, de Roos A, Radder J: Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003, 42: 328-335. 10.1016/S0735-1097(03)00625-9.CrossRefPubMed
2.
Kannel W, Hjortland M, Castelli W: Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974, 34: 29-34. 10.1016/0002-9149(74)90089-7.CrossRefPubMed
3.
Jain M, Liao R, Miller T, LeBrasseur N, Sawyer D: Mechanisms in the pathogenesis of diabetic cardiomyopathy. Curr Opin Endocrinol Diabetes. 2003, 10: 251-255. 10.1097/00060793-200308000-00004.CrossRef
4.
Picano E: Diabetic cardiomyopathy: the importance of being earliest. J Am Coll Cardiol. 2003, 42: 454-457. 10.1016/S0735-1097(03)00647-8.CrossRefPubMed
5.
Schannwell C, Schneppenheim M, Perings S, Plehn G, Strauer BE: Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology. 2002, 98: 33-39. 10.1159/000064682.CrossRefPubMed
6.
Kankaanpaa M, Lehto H-R, Parkka JP, Komu M, Viljanen A, Ferrannini E, Knuuti J, Nuutila P, Parkkola R, Iozzo P: Myocardial Triglyceride Content and Epicardial Fat Mass in Human Obesity: Relationship to Left Ventricular Function and Serum Free Fatty Acid Levels. J Clin Endocrinol Metab. 2006, 91 (11): 4689-4695. 10.1210/jc.2006-0584.CrossRefPubMed
7.
McGavock J, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine B, Raskin P, Victor R, Szczepaniak L: Cardiac steatosis in diabetes mellitus. A 1H-magnetic resonance spectroscopy study. Circulation. 2007, 116: 1170-1175. 10.1161/CIRCULATIONAHA.106.645614.CrossRefPubMed
8.
Zhou Y, Graybirn P, Karim A, Scimabukuro M, Higa M, Baetens D, Orci L, Unger R: Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci. 2000, 97: 1784-1789. 10.1073/pnas.97.4.1784.PubMedCentralCrossRefPubMed
9.
Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A, Han X, Gross R, Kozak R, Lopaschuk G, Kelly DP: The cardiac phenotype induced by PPAR alpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002, 109: 121-130.PubMedCentralCrossRefPubMed
10.
An D, Rodrigues B: Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2006, 291 (4): H1489-H1506. 10.1152/ajpheart.00278.2006.CrossRefPubMed
11.
Christoffersen V, Bollano E, Lindegaard M, Bartels E, Goetz J, Andersen C, Nielsen L: Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology. 2003, 144: 3483-3490. 10.1210/en.2003-0242.CrossRefPubMed
12.
Chiu H, Kovacs A, Ford D, Hsu F, Garcia R, Herrero P, Saffitz J, Schaffer J: A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001, 107: 813-822. 10.1172/JCI10947.PubMedCentralCrossRefPubMed
13.
Rijzewijk LJvdMR, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ: Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008, 52: 1793-1799. 10.1016/j.jacc.2008.07.062.CrossRefPubMed
14.
Schaffer J: Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003, 14: 281-287. 10.1097/00041433-200306000-00008.CrossRefPubMed
15.
Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz E, Merkel M, Bensadoun A, Homma S, Goldberg IJ: Lipoprotein lipase on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest. 2003, 111: 419-426.PubMedCentralCrossRefPubMed
16.
Litwin S, Raya T, Gay R: Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. Am J Physiol. 1990, 258: H51-H56.PubMed
17.
Nielsen L, Bartels E, Bollano E: Overexpression of apolipoproteinB100 in the heart impedes cardiac triglyceride accumulation and development odf cardiac dysfunction in diabetic mice. J Biol Chem. 2002, 277: 27014-27020. 10.1074/jbc.M203458200.CrossRefPubMed
18.
Ueno M, Suzuki J, Zenimaru Y, Takahashi S, Koizumi T, Noriki S, Yamaguchi O, Otsu K, Shen W, Kraemer F, Miyamori I: Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am J Physiol Endocrinol Metab. 2008, 294: E1109-E1118. 10.1152/ajpendo.00016.2008.CrossRefPubMed
19.
Taegtmeyer H, McNulty P, Young M: Adaptation and maladaptation of the heart in diabetes: Part I General concepts. Circulation. 2002, 105: 1727-1733. 10.1161/01.CIR.0000012466.50373.E8.CrossRefPubMed
20.
Young M, Guthrie P, Razeghi P, Leighton B, Abbasi S, Patil S, Youker K, Taegtmeyer H: Impaired lon-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes. 2002, 51: 2587-2595. 10.2337/diabetes.51.8.2587.CrossRefPubMed
21.
Luiken J, Arumugam Y, Dyck D, Bell R, Pelsers M, Turcotte L, Tandon N, Glatz J, Bonen A: Increased rate of fatty acid uptake and plasmalemnal fatty acid transporters in obese Zucker rats. J Biol Chem. 2001, 276: 40567-40573. 10.1074/jbc.M100052200.CrossRefPubMed
22.
Guan Y, Hao C, Cha D, Rao R, Lu W, Kohan D, Magnuson M, Redha R, Zhang Y, Breyer M: Thiazolidinediones expand body fluid volume through PPARgama stimulation of EnaC-mediated renal salt absorption. Nature Med. 2005, 11: 861-866. 10.1038/nm1278.CrossRefPubMed
23.
Wang C, Chen W, Lin W, Chen M, Lee YT: Glitazones and heart failure: critical appraisal for the clinician. Circulation. 2003, 107: 1350-1354. 10.1161/01.CIR.0000054675.30348.9A.CrossRefPubMed
24.
Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M: Mechanisms of the triglyceride and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes. 2002, 51: 3486-3491. 10.2337/diabetes.51.12.3486.CrossRefPubMed
25.
Kim H, Haluzik M, Asghar Z, Yau D, Joseph J, Fernandez A, Reitman M, Yakar S, Stannard B, Heron-Milhaet L, Wheeler MB, LeRoith D: PPAR-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes. 2003, 52: 1770-1778. 10.2337/diabetes.52.7.1770.CrossRefPubMed
26.
Aasum E, Belke D, Severson D, Riemersma R, Cooper M, Andreassen M, Larsen T: Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17. a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 0744, 283: H949-H957.CrossRef
27.
Kim S, Zhao Z, Lee Y, Lee K, Kang SM, Choi D, Lim S, Chung N, Lee H, Cha B: Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev. 2003, 19: 487-493. 10.1002/dmrr.410.CrossRefPubMed
28.
Finck B, Han X, Courtois M, Aimond F, Nerbonne J, Kovacs A, Gross R, Kelly D: A critical role for PPAR-alpha mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci. 2003, 100: 1226-1231. 10.1073/pnas.0336724100.PubMedCentralCrossRefPubMed
29.
Wang P, Lloyd SG, Zeng H, Bonen A, Chatham JC: Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol. 2005, 288 (5): H2102-2110. 10.1152/ajpheart.00935.2004.CrossRefPubMed
30.
31.
Smith A, Mullen K, Junkin KA, Nickerson J, Adrian Chabowski A, Arend Bonen A, Dyck DJ: Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia. Am J Physiol Endocrinol Metab. 2007, 296: E172-E181. 10.1152/ajpendo.00677.2006.CrossRef
32.
Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I: Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptyl peptidase IV inhibitor in Zucker fa/fa rats. JPET. 2004, 310: 614-619. 10.1124/jpet.103.064964.CrossRef
33.
Yamauchi TKJ, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002, 8: 1288-1295. 10.1038/nm788.CrossRefPubMed
34.
Pineiro RIM, Gallego R, Raghay K, Eiras S, Rubio J, Dieguez C, Gualillo O, Gonzalez-Juanatey JR, Lago F: Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 2005, 579: 5163-5169. 10.1016/j.febslet.2005.07.098.CrossRefPubMed
35.
Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T: Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005, 54: 3358-3370. 10.2337/diabetes.54.12.3358.CrossRefPubMed
36.
Stanley W, Lopaschuk G, McCormack J: Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997, 34: 25-33. 10.1016/S0008-6363(97)00047-3.CrossRefPubMed
37.
Brownsey R, Boone A, Akkard M: Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res. 1997, 34: 3-24. 10.1016/S0008-6363(97)00051-5.CrossRefPubMed
38.
Iglarz M, Touyz R, Viel E, Paradis P, Amiri F, Diep Q, Schiggrin E: PPARalpha and PPARgamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension. 2003, 42: 737-743. 10.1161/01.HYP.0000083511.91817.B1.CrossRefPubMed
39.
Ogata T, Miyauchi T, Sakai S, Irukayama-Yomobe Y, Goto K, Yamaguchi I: Stimulation of PPARalpha attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci. 2002, 103: 284S-288S.CrossRefPubMed
40.
Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Yomobe Y, Yamaguchi I: Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the PPAR alpha activator fenofibrate, partly by suppressing inflammatory responses assocaited with the nuclear factor Kappa-B pathway. J Am Coll Cardiol. 2004, 43: 1481-1488. 10.1016/j.jacc.2003.11.043.CrossRefPubMed
41.
Finck B: The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heart. Curr Opin Clin Nutr Metab Care. 2004, 7: 391-396. 10.1097/01.mco.0000134371.70815.32.CrossRefPubMed
42.
Gilde A, Lee van der K, Willemsen P, Chinetti G, Leij van der F, Vusse van der G, Staels B, van Bilsen M: Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003, 92: 518-524. 10.1161/01.RES.0000060700.55247.7C.CrossRefPubMed
43.
Brandt J, Gjouadi F, Kelly D: Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem. 1998, 273: 23786-23792. 10.1074/jbc.273.37.23786.CrossRefPubMed
44.
Aasum E, Cooper M, Severson D, Larsen T: Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol. 2005, 83: 183-190. 10.1139/y04-139.CrossRefPubMed
45.
Kim J, Lewin T, Cleman R: Expression and characterization of recombinant rat acyl-CoA synthetases 1,4 and 5. J Biol Chem. 2001, 276: 24667-24673. 10.1074/jbc.M010793200.CrossRefPubMed
46.
Fujino T, Kang MJ, Suzuki H, Iijima H, Yamamoto T: Molecular characterization and expression of rat Acyl-CoA synthetase 3. J Biol Chem. 1996, 271: 16748-16752. 10.1074/jbc.271.28.16748.CrossRefPubMed
47.
Suzuki H, Kawarabayasi Y, Kondo J, Abe T, Nishikawa K, Kimura S, Hashimoto T, Yamamoto T: Structure and regulation of rat long-chain acyl-CoA synthetase. J Biol Chem. 1990, 265: 8681-8685.PubMed
48.
Durgan DJ, Smith JK, Hotze MA, Egbejimi O, Cuthbert KD, Zaha VG, Dyck JRB, Abel ED, Young ME: Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol. 2006, 290 (6): H2480-2497. 10.1152/ajpheart.01344.2005.CrossRefPubMed
49.
Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, Gomez-Perez FJ, Rull JA: The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial. J Clin Endocrinol Metab. 2004, 89 (8): 3943-3948. 10.1210/jc.2004-0019.CrossRefPubMed
50.
Hattori Y, Suzuki K, Hattori S, Kasai K: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006, 47: 1183-1188. 10.1161/01.HYP.0000221429.94591.72.CrossRefPubMed
51.
Musso GGR, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, Cassader M, Durazzo M, Rizzetto M, Pagano G: Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2005, 2438-2446. 10.1111/j.1572-0241.2005.00297.x.
52.
Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K: Globular adiponectin activates NFkappaB ans AP-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes. 2007, 56: 804-808. 10.2337/db06-1405.CrossRefPubMed
53.
Hattori Y, Hattori S, Kasai K: Globular Adiponectin Activates Nuclear Factor-{kappa}B in Vascular Endothelial Cells, Which in Turn Induces Expression of Proinflammatory and Adhesion Molecule Genes. Diabetes Care. 2006, 29 (1): 139-141. 10.2337/diacare.29.01.06.dc05-1364.CrossRefPubMed
54.
Tsatsanis C, Zacharioudakia V, Androulidakia A, Dermitzakia E, Charalampopoulosb I, Minasb V, Gravanisb A, Margiorisa A: Adiponectin induces TNF-α and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun. 2005, 335: 1254-1263. 10.1016/j.bbrc.2005.07.197.CrossRefPubMed
55.
Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocrine Rev. 2005, 26: 439-451. 10.1210/er.2005-0005.CrossRef
Metadata
Title
Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model – the Zucker diabetic rat
Authors
Fabien Forcheron
Alexandra Basset
Pauline Abdallah
Peggy Del Carmine
Nicolas Gadot
Michel Beylot
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2009
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-8-16

Other articles of this Issue 1/2009

Cardiovascular Diabetology 1/2009 Go to the issue

Original investigation

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type

Original investigation

Cardiomyopathy in offspring of diabetic rats is associated with activation of the MAPK and apoptotic pathways

Original investigation

The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender

Original investigation

Folic acid supplementation normalizes the endothelial progenitor cell transcriptome of patients with type 1 diabetes: a case-control pilot study

Original investigation

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment

Original investigation

Cardiovascular risk factors in Assyrians/Syrians and native Swedes with type 2 diabetes: a population-based epidemiological study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits